Current perspective - trastuzumab.
This article will review the available clinical data on the efficacy of trastuzumab in the treatment of both early advanced breast cancer.
Hall
Peter S
PS
University of Leeds, UK. p.s.hall@leeds.ac.uk
Cameron
David A
DA
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics; D017024:Chemotherapy, Adjuvant; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D018734:Genes, erbB-2; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000235:genetics; D000068878:Trastuzumab; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068878:Trastuzumab